HspE7
Navigation Links
HspE7 in Medical News
Nventa presents HspE7 data at international HPV conference
Preclinical Data Indicate New HspE7 Promotes More Potent Immune Responses SAN DIEGO, CA, Nov. 5 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) today presented additional preclinical data on new HspE7 at the 24th International Papillomavirus conference, the largest annu...HspE7 in Medical Technology
Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
All Patients in Cohort 3 Demonstrated Improvement in T-Cell Responses Further Supporting the Therapeutic Potential of HspE7 SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced positive immunological data from the third cohort of...Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
- HspE7 Phase 2 Trial for Cervical Dysplasia to Begin Mid-2008 - SAN DIEGO, April 24 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of the fourth and final cohort of patients in its Phase 1...Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
3 out of 4 Patients in Cohort 2 Demonstrate T-Cell Responses Indicating Potential HspE7 Therapeutic Benefit SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced interim immunological data from the first two cohorts of i...Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
SAN DIEGO, March 11 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that the Company has completed enrollment and initiated dosing of the fourth and final cohort of patients in its Phase 1 dose escalation trial. This study examines the safety of its l...Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
- HspE7 Well Tolerated; Fourth Cohort to be Dosed Shortly - SAN DIEGO, March 3 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of its third cohort of patients in a Phase 1 clinical trial o...- 78 Percent of Patients Showed Complete Response or Reduction of Lesion Size by More than Fifty Percent - SAN DIEGO, CA, March 05, 2007 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation today announced the presentation of positive results from a clinical trial examining the safety an...
Initiation of Coverage Informational Review Issued by Scimitar Equity Research
...tp://www.nventacorp.com . About HspE7, Nventa's Lead Product Candidate: hspe7 is a novel therapeutic vaccine candidate for the treatment of diseases caus...s (HPV), one of the most common sexually transmitted diseases in the world. hspe7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses ...HspE7 in Biological Technology
Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
SAN DIEGO, CA, Dec. 6 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that the Company has completed enrollment and initiated dosing of the second cohort of patients in its Phase 1 dose escalation trial examining the safety of its lead candidate, HspE7...Nventa announces publication of HspE7 data
- HspE7 Demonstrates Ability to Elicit Long-Lasting Tumor Protection In Vivo; Lead Candidate May Have Utility in HPV-infected Patients With Invasive Cancer and/or HIV - SAN DIEGO, CA, Sept. 24 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) today ...Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
- Conference Call on September 13 to Discuss Phase 1 Trial and Other Major Milestones - SAN DIEGO, CA, Sept. 10 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) today announced the initiation of its Phase 1 clinical trial to assess the safety...Nventa updates progress of cervical dysplasia trial with new HspE7
-- Company Completes Enrollment in First Cohort -- SAN DIEGO, CA, Oct. 18 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) today announced that the Company has completed enrollment of the first cohort in its Phase 1 clinical trial to assess the safety and tol......e fourth cohort were administered 500 mcg of hspe7 and 2,000 mcg of Poly-ICLC. These data support doses of 500 mcg of hspe7 and 1,000-2,000 mcg of Poly ICLC as appropri...nformation concerning: the immunologic activity of hspe7 in treating CIN; that we identified an optimal dos...
Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
...nclude Phase 2 clinical studies that will evaluate hspe7 as a potential treatment for both low-grade cervic... do, that such studies will not support the use of hspe7 as a treatment for CIN 1 or CIN 2/3; that we will ...nned and that such studies will support the use of hspe7 as a treatment for CIN 1 and CIN 2/3; that we will...Nventa Appoints Gordon H. Busenbark to Board of Directors
...at Burroughs Corporation. He received a bachelor of science degree in accounting and an MBA from the University of Utah in Salt Lake City. "Nventa's hspe7 therapeutic vaccine for the treatment of HPV-related diseases places the company at the center of a very exciting segment of the drug development indu...Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
... - Company Advancing Lead Candidate hspe7 into Phase 2 Clinical Trial in ...sia clinical trial examining the safety of new hspe7 leading to the recent completion of enrollment...conference demonstrating that co-administering hspe7 with certain adjuvants promotes more potent re...Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
...the first cohort of patients in the Company's hspe7 Phase 1 clinical trial in cervical intraepithelial...ce and Clinical Workshop that demonstrate that new hspe7 promotes more potent immune responses; - G...ccine Immunology demonstrating ability of new hspe7 to elicit long-lasting tumor protection in vivo, ...Other TagsIntermittentMentallyRiskyHypnosisFoodsFoodsEasingEasingEasingAbstinenceSymptomsSymptomsSymptomsEfficacyEfficacyOther Contentsconditionsconditionsconditionsconditionsconditionsconditionsconditionsconditionsconditionsconditionsmovementsmovementsmovementsmovementsmovementsmovementsmovementsmovementsdroopingdroopingeyelideyelideyelidplanningplanningplanningplanningplanningplanningeyeseyeseyeseyeseyeseyeseyeseyestrainthrivethrivethrivethrivethrivethrive
IntermittentStockingsBiofeedbackMentallyRiskyAdoptingHypnosisFoodsEasingAbstinenceSymptomsEfficacyLycopeneMixing
(Date:11/27/2009)...ov.27/PRNewswire-FirstCall/--TheGymboreeCorporatio...willpresentattheNASDAQOMX23rdInvestorProgram,which...esday,December2,2009,at11:45a.m.GMT. ,, Toliste...ationovertheInternet,pleaselogontowww.gymboree.com...storandMediaRelations"andthen"ConferenceCalls&...
(Date:11/27/2009)...INE,France,Nov.27/PRNewswire/--TeamGarmin-Slipstre...dtoethicalsportinganddevelopingthenextgenerationof...mGarmin-TransitionswiththeadditionofTransitionsOpt...world,sleadingmanufacturerofadaptiveeyewear,offeri...selectionofspectaclelensessuchasTransitionslensesa...
(Date:11/27/2009)... XenaCare Holdings has announced that it has be...n, one of the largest nonprofit organizations dedi...ation. , Delray Beach, FL...nc. (OTCBB: XCHO), a company specializing in the m...hcare products, has announced today that is has be...
(Date:11/27/2009)... unprecedented medical, economic burdens, study pr...ws) -- The number of people with diabetes in the U...5 years, a new study predicts. , That would bri...with the disease, up from 23.7 million today. , ,...th diabetes will triple, the study also warns, ris...
(Date:11/27/2009)... Voyant Health™ announced today that Spec...its TraumaCad Enterprise orthopedic templating sol... , (PRWEB) November 27, 20...ectrum Health (Grand Rapids, Michigan) has license...olution and its TraumaCad Extend workflow solution...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3[0] The Gymboree Corporation to Present at NASDAQ OMX 23rd Investor Program[0] Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor[0] XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation [0] Diabetes Cases Expected to Double in 25 Years[0] Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend
(Date:11/26/2009)...9 What are the bare essentials of life, the indis...at can survive on its own? Can we describe the mol...tire organism functions as a system? These are jus...ership between the European Molecular Biology Labo...re de Regulacio Genmica (CRG) in Barcelona, Spain,...
(Date:11/25/2009)...police officers and ambulance workers faced a terr...plex. They battled to save people from the collaps...ires and evacuated as many people as they could in...e. And making their jobs even harder was the probl...their relatives jammed mobile networks with calls ...
(Date:11/25/2009)...be just as vital to your health as what you eat, f...cal Studies. Their experiments in mice revealed th...es in the liverthe body,s metabolic clearinghousei...body,s circadian clock as conventional wisdom had ...of a large number of genes completely independent ...
Breaking Biology News(10 mins):First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Magic box for mission impossible 2Magic box for mission impossible 3Feeding the clock 2Feeding the clock 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 14743 1DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 14743 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 14743 3Transgenomic Inc Reports Third Quarter 2009 Results 14739 1Transgenomic Inc Reports Third Quarter 2009 Results 14739 2Transgenomic Inc Reports Third Quarter 2009 Results 14739 3Transgenomic Inc Reports Third Quarter 2009 Results 14739 4Transgenomic Inc Reports Third Quarter 2009 Results 14739 5Transgenomic Inc Reports Third Quarter 2009 Results 14739 6Transgenomic Inc Reports Third Quarter 2009 Results 14739 7Orange County Dermatologist Garners Outstanding Results With New Thermage CPT 28R 29 6034 1Orange County Dermatologist Garners Outstanding Results With New Thermage CPT 28R 29 6034 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |